The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.
This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product. The following approaches to cancer therapeutics are covered in the report:
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level.
Coverage of the Most Recent Product and Trends
The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:
As part of its comprehensive coverage, the following companies are profiled:
This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product. The following approaches to cancer therapeutics are covered in the report:
- Biotherapeutics
- Monoclonal Antibodies
- Interleukins/ Interferons
- Kinases and Other Treatments
- Chemotherapy
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Hormone Therapy
- Corticosteroids
- Hormone Antagonists/ Antagonists
- Aromatase Inhibitors
- SERMS
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level.
Coverage of the Most Recent Product and Trends
The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:
- Insurance and Reimbursement
- Drug Costs
- Personalized Medicine
- Alliances, Acquisitions and Licensing Agreements
- Alcohol’s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Marketing and Distribution Trends
- Geographical Trends
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
As part of its comprehensive coverage, the following companies are profiled:
- AstraZeneca (coverage of Arimidex, Casodex, Faslodex, Zoladex, Iressa, Nolvadex and other products)
- Biogen IDEC (coverage of Rituxan and other products)
- Bristol-Myers Squibb (coverage of Erbitux, Taxol, Ixempra, Sprycel and other products)
- Eli Lilly (coverage of Alimta, Gemzar and other products)
- Genentech (coverage of Avastin, Herceptin, Rituxan )
- Johnson & Johnson (coverage of Doxil, Velcade, Leustatin)
- Merck & Company (coverage of Zolinza and other products)
- Novartis (coverage of Femara, Gleevec/Glivec, Tasigna, Sandostatin, Proleukin, Afinitor and other products)
- Pfizer (coverage of Camptosar and Sutent)
- Roche (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs)
- Sanofi-Aventis (coverage of Taxotere, Eloxatine and others)
- Schering-Plough (coverage of Intron A, Timodar/Temodal, Caelyx/Doxil and pipeline plans)
- CHAPTER ONE: EXECUTIVE SUMMARY
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
- CHAPTER TWO: INTRODUCTION
- What is Cancer
- Biochemistry of Cancer Cells
- Carcinogen Metabolism
- Causes of Cancer Growth
- Environmental Factors, DNA, RNA
- Cellular Oncogenes
- Tumor Suppressor Genes
- History and Growth of the Cancer Treatment Market
- Growth of Cancer Development
- Industry Structure
- Product Segments and Technology
- Chemotherapy: At a Glance
- Hormone Therapy: At A Glance
- Biotherapy: AT a Glance
- Radiation Therapy: At a Glance
- Demographics and Statistics
- Global Cancer Statistics
- Demographics
- Aging Population
- Life Expectancy and Cancer
- Description of Cancers
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck
- Kidney
- Leukemia
- Liver
- Lung Cancer
- Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroblastoma
- Ovarian Cancer
- Pancreas
- Prostate Cancer
- Stomach Cancer
- CHAPTER THREE: CHEMOTHERAPY
- Overview
- Product Descriptions and Examples
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- CHAPTER FOUR: HORMONE THERAPY
- Overview
- Product Descriptions and Examples
- Corticosteroids
- Synthetic Corticosteroids
- Hormone Agonists and Antagonists
- Estrogens
- Androgens
- Antiestrogens
- Antiandrogens
- Gonadotropin-releasing Hormone Analogues
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- CHAPTER FIVE: BIOTHERAPEUTICS
- Overview
- Product Descriptions and Examples
- Monoclonal Antibodies
- Avastin (bevacizumab)
- Campath (alemtuzumab)
- Erbitux (cetuximab)
- Herceptin (trastuzumab)
- Mylotarg (gemtuzumab ozogamicin)
- Panorex (edrecolomab)
- Rituxan (rituximab)
- Vectibix (panitumumab)
- Interleukins/Interferons
- Alferon-N
- Infergen
- Intron A
- Proleukin
- Roferon A
- Other Biotherapy
- Antisense Oligonucleotides
- Apoptosis
- Growth Factors
- Methylation
- P53
- Ras Protein Drugs
- Regulatory Enzymes
- Proteasome Inhibitors
- Radioimmunotherapy
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- Europe Market
- Japan Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Overview
- Total Market Size and Forecast
- Competitive Landscape
- CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Introduction
- Insurance and Reimbursement Issues
- Cancer Drug Costs
- Personalized Medicine
- Targeted Cancer Therapy
- Pharmacogenomics
- Alliances Acquisitions and Licensing Agreements
- Patient-Reported Outcomes
- Alcohol’s Affect on Cancer Incidence
- Healthy Lifestyles Continue to Show Promise for Cancer Prevention
- Possibility for a Healthier U.S. Population
- Cancer Trends
- Marketing and Distribution Trends
- Geographical Trends
- United States
- Europe
- Japan
- Elderly Clinical Trial Involvement
- Late-Stage Drug Development Trends
- CHAPTER EIGHT: CORPORATE PROFILES
- Introduction
- AstraZeneca plc
- Biogen IDEC, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly & Company
- Genentech, Inc.
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi-Aventis
- Schering-Plough Corporation
- CHAPTER NINE: COMPANY DIRECTORY
- LIST OF EXHIBITS
- EXECUTIVE SUMMARY
- Table 1-1 World Cancer Treatment Market, 2004-2013
- Figure 1-1 World Cancer Treatment Market, 2004-2013
- INTRODUCTION
- Table 2-1 Viruses Associated with Cancer in Humans
- Table 2-2 Cancer Therapy Approvals per Year in the United States, 1970-2008
- Figure 2-1 Cancer Therapy Approvals per Year in the United States, 1970-2008
- Table 2-3 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Figure 2-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Table 2-4 Cancer Incidence and Mortality by Country 2007
- Figure 2-3 Cancer Incidence by Country 2007
- Figure 2-4 Cancer Deaths by Country 2007
- Table 2-5 Total Cancer Incidence by Sex and Country, 2007
- Figure 2-5 Total Cancer Incidence by Sex and Country, 2007
- Table 2-6 World Population by Selected Geographical Region, 2007 - 2050
- Figure 2-6 World Population by Selected Geographical Region, 2007-2050
- Table 2-7 Estimated World Population by Age and Geographical Region, 2007
- Figure 2-7 Estimated World Population by Age and Geographical Region, 2007
- Table 2-8 Percent Population Over 65 by Year and Region
- Figure 2-8 Estimated World Population by Age, 2007 and 2050
- Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008
- Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008
- Table 2-10 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
- Table 2-11 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004
- Figure 2-12 Approved Cancer Therapies in the United States by Indication
- Table 2-10 Types Of Leukemia
- Table 2-11 Types Of Primary Lung Cancer
- Table 2-12 Classification Of Non-hodgkin’s Lymphomas
- Table 2-13 Malignant Conditions Of The Skin
- CHEMOTHERAPY
- Table 3-1 Leading Products, 2008
- Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved Indications, 2007 through 2009
- Table 3-3 World Chemotherapy Market, 2004-2013
- Figure 3-1 World Chemotherapy Market, 2004-2013
- Table 3-4 World Chemotherapy Market, Market by Product Classification, 2004-2013
- Figure 3-2 World Chemotherapy Market
- Figure 3-3 World Chemotherapy Market
- Figure 3-4 World Chemotherapy Market
- Figure 3-5 World Chemotherapy Market
- Figure 3-6 World Chemotherapy Market
- Figure 3-7 World Chemotherapy Market
- Table 3-5 World Chemotherapy Market
- Figure 3-8 World Chemotherapy Market
- Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market Revenues, 2008
- Figure 3-9 World Chemotherapy Market, Leading Suppliers Market Share, 2008
- HORMONE THERAPY
- Table 4-1 Leading Products, 2008
- Table 4-2 Newly Approved Hormone Cancer Therapies and Additional Indications 2007 through 2009
- Table 4-3 World Hormone Therapy Market, 2004-2013
- Figure 4-1 World Hormone Therapy Market, 2004-2013
- Table 4-4 World Hormone Therapy Market, Market by Product Classification, 2004-2013
- Figure 4-2 World Hormone Therapy Market, Market by Product Classification Revenues, 2004-2013
- Figure 4-3 World Hormone Therapy Market, Market by Product Classification and Percent Distribution, 2004-2013
- Figure 4-4 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2008
- Figure 4-5 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2013
- Figure 4-5 World Hormone Therapy Market
- Figure 4-6 World Hormone Therapy Market
- Table 4-6 World Hormone Therapy Market
- Figure 4-7 World Hormone Therapy Market
- Table 4-7 World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2008
- Figure 4-8 World Hormone Therapy Market, Leading Suppliers Market Share, 2008
- BIOTHERAPEUTICS
- Table 5-1 Leading Products, 2008
- Table 5-2 Newly Approved Biological Therapies and Additional Indications, 2007 through March 2009
- Table 5-3 World Cancer Biotherapeutics Market, 2004-2013
- Figure 5-1 World Cancer Biotherapeutics Market, 2004-2013
- Table 5-4 World Cancer Biotherapeutics Market Market by Product Type, (Monoclonal Antibodies, Interleukins/ Interferons, Other) 2004-2013
- Figure 5-2 World Cancer Biotherapeutics Market, Market by Product Classification (Monoclonal Antibodies, Interleukins/ Interferons, Other) OtherRevenues, 2004-2013
- Figure 5-3 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Distribution, 2004-2013
- Figure 5-4 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2008
- Figure 5-5 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2013
- Figure 5-6 World Cancer Biotherapeutics Market
- Figure 5-7 World Cancer Biotherapeutics Market
- Table 5-5 World Cancer Biotherapeutics Market
- Figure 5-8 World Cancer Biotherapeutics Market
- Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2008
- Figure 5-9 World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2008
- WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST
- Table 6-1 World Cancer Market Market by Product Type, 2004-2013
- Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2004-2013
- Figure 6-2 World Cancer Market, Market by Product Type and Percent Distribution, 2004-2013
- Figure 6-3 World Cancer Market, Market by Product Type and Percent Market Share, 2008
- Figure 6-4 World Cancer Market, Market by Product Type and Percent Market Share, 2013
- Table 6-2 World Cancer Market, Top Five Suppliers Shares by Market Revenues, 2008
- Figure 6-5 World Cancer Market, Top Five Suppliers Market Share, 2008 Issues and Trends Affecting the Cancer Market
- ISSUES AND TRENDS AFFECTING THE CANCER MARKET
- Table 7-1 Obesity Rates by State
- Table 7-2 Select Products in Development by Product Name
- Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications
- CORPORATE PROFILES
- Figure 8-1 Late stage Cancer Therapies in Development for Leading Companies
